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various nutritional factors have been investigated as potential risk factors for ASD
development, including omega-3 polyunsaturated fatty acids (PUFAs) and vitamin D
deficiency. In fact, both omega-3 PUFAs and vitamin D are important for brain
development and function.
Case report: Herein, we report the case of a 23-year-old young adult male with autism
who was referred to our Unit due to a 12 months history of cyclic episodes of
restlessness, agitation, irritability, oppositional and self-injurious behaviours.
Laboratory tests documented a markedly altered omega-6/omega-3 balance, along
with a vitamin D deficiency, as assessed by serum levels of 25-hydroxyvitamin D.
Omega-3 and vitamin D co-supplementation was therefore started, with remarkable
improvements in ASD symptoms throughout a 24 months follow-up period. A brief
review of the literature for interventional studies evaluating the efficacy of omega-3 or
vitamin D supplementation for the treatment of ASD-related symptoms is also provided.
Conclusion: To our knowledge, this is the first case reporting remarkable beneficial
effects on ASD symptoms deriving from omega-3 and vitamin D combination therapy.
This case report suggests omega-3 and vitamin D co-supplementation as a potential
safe-effective therapeutic strategy to treat core symptoms of ASD. However, larger
studies are needed to evaluate the real effectiveness of such therapeutic approach in a
broader sample of ASD patients.
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Omega-3 PUFAs and vitamin D co-supplementation as a safe-effective 
therapeutic approach for core symptoms of autism spectrum disorder: case 
report and literature review 
Abstract 
Introduction: Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders 
characterized by abnormal development of cognitive, social, and communicative skills. Although 
ASD aetiology and pathophysiology are still unclear, various nutritional factors have been 
investigated as potential risk factors for ASD development, including omega-3 polyunsaturated fatty 
acids (PUFAs) and vitamin D deficiency. In fact, both omega-3 PUFAs and vitamin D are important 
for brain development and function.  
Case report: Herein, we report the case of a 23-year-old young adult male with autism who was 
referred to our Unit due to a 12 months history of cyclic episodes of restlessness, agitation, irritability, 
oppositional and self-injurious behaviours. Laboratory tests documented a markedly altered omega-
6/omega-3 balance, along with a vitamin D deficiency, as assessed by serum levels of 25-
hydroxyvitamin D. Omega-3 and vitamin D co-supplementation was therefore started, with 
remarkable improvements in ASD symptoms throughout a 24 months follow-up period. A brief 
review of the literature for interventional studies evaluating the efficacy of omega-3 or vitamin D 
supplementation for the treatment of ASD-related symptoms is also provided. 
Conclusion: To our knowledge, this is the first case reporting remarkable beneficial effects on ASD 
symptoms deriving from omega-3 and vitamin D combination therapy. This case report suggests 
omega-3 and vitamin D co-supplementation as a potential safe-effective therapeutic strategy to treat 
core symptoms of ASD. However, larger studies are needed to evaluate the real effectiveness of such 
therapeutic approach in a broader sample of ASD patients.  
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Introduction     
Autism Spectrum Disorder (ASD) is a group of heterogeneous neurodevelopmental disorders 
occurring during the first years of life and characterized by abnormal development of cognitive, 
social, and communicative skills, often presenting with restricted patterns of interests, repetitive 
behaviours or movements, and sensory processing abnormalities (1, 2). To date, pharmacological 
treatments for ASD are particularly limited and almost exclusively targeted to their symptoms (3). 
Current limitations in development of novel treatments are certainly represented by the hazy ASD 
pathophysiology, as well as the paucity of clear diagnostic biomarkers and outcome measures for 
clinical trials (3, 4). Nonetheless, the prevalence of ASD dramatically raised over the last four decades 
(5). Even though genetic factors play a critical role in ASD (6), the aetiology of autism is likely to be 
multifactorial (7). In fact, the interaction between genetic and environmental factors seems to cause 
most of ASD (8). During the last years, the role of different environmental factors (e.g. nutritional, 
medications, maternal infections during pregnancy, etc.) in ASD has been extensively reviewed, with 
a growing interest in nutritional factors (9). Of note, the role of omega-3 and omega-6 polyunsaturated 
fatty acids (PUFAs) and vitamin D in development, prevention and treatment of ASD has been largely 
investigated (10-13).  
Omega-3 PUFAs are essential nutrients that need to be provided through dietary sources or 
supplements (14). Importantly, omega-3 are major components of neuronal membranes and regulate 
important properties, such as neurite growth, neuronal survival, membrane fluidity, 
neurotransmission, neurogenesis, and synaptic plasticity (15-17). Hence, omega-3 are deemed 
necessary for a proper brain development (18). Preclinical studies showed that omega-3 deficiency 
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during development affects learning and cognitive behaviour (19, 20). Furthermore, omega-3 
deficiency appears to be involved in different psychiatric disorders, including ASD (21-23). 
Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and α-linolenic acid (ALA) are highly 
concentrated in the brain, where they play neuroprotective, anti-oxidant, and anti-inflammatory roles 
(15). In particular, EPA and DHA are the precursors of specific autacoids known as resolvins, which 
are involved in the resolution of inflammation (24). Conversely, omega-6 PUFAs (particularly 
arachidonic acid, AA) compete with omega-3 and exert opposing properties, promoting 
inflammation, thrombosis and vasoconstriction through their derived-metabolite eicosanoids (25, 26). 
Modern western diets have progressively evolved toward a ratio of omega-6 to omega-3 of 
approximately 15/1 - 16.7/1 (25). Importantly, the increased ratio of omega-6 to omega-3 has been 
shown to contribute to pathogenesis of several disease, such as cancer, obesity, cardiovascular 
disease, and autoimmune and inflammatory disorders (14, 25, 27). This could have relevant 
implications even for ASD, which is characterized by reduced cerebral blood flow and 
neuroinflammation (28, 29). Moreover, the marked rise in the prevalence of ASD observed during 
last decades appears to parallel dietary changes in essential fatty acids intake, which has gradually 
shifted towards higher amounts of omega-6 compared to omega-3 (30), suggesting the omega-3 
deficient diet as a potential risk factor for ASD development (10).  Evidence also shows that children 
with ASD have lower levels of plasma and erythrocyte membrane omega-3, as well as a higher 
AA/EPA ratio compared with healthy controls (22, 31). These findings could be related to low omega-
3 dietary intake and/or differences in fatty acid metabolism and incorporation into cell membranes of 
ASD children (31). 
Vitamin D production is mostly UVB-mediated through adequate sun exposure, with a minor fraction 
secured by dietary intake (32). According to the Endocrine Society guidelines, vitamin D deficiency 
is defined as serum levels of 25(OH)D (25-hydroxyvitamin D, the major circulating metabolite of 
vitamin D) below 50 nmol/L, whereas vitamin D insufficiency is defined as serum levels ranged 
4 
 
between 52.5 and 72.5 nmol/L (33). Vitamin D has been shown to play several extra-skeletal effects, 
other than the well-known regulation of calcium-phosphorus and bone homeostasis (34). Importantly, 
a growing body of evidence suggests an involvement of vitamin D deficiency in ASD (12, 13). The 
autism-vitamin D theory has been first introduced by Cannell, which proposed gestational and early 
childhood vitamin D deficiency as the primary environmental trigger for autism development (35). 
Vitamin D acts as a neuroactive steroid playing an important role in brain development and mature 
brain function (36, 37). Accordingly, both vitamin D receptor (VDR) and 1-hydroxylase - the 
enzyme responsible for the synthesis of the active form of vitamin D, namely 1,25-dihydroxyvitamin 
D - have been found in human brain (38). Moreover, autism prevalence is higher in areas of lower 
UVB penetration (39). Different studies and meta-analyses have shown that children and adults with 
ASD exhibit significantly lower levels of serum 25(OH)D compared to healthy controls, further 
suggesting that vitamin D deficiency represents a risk factor for ASD  (40-43). Furthermore, lower 
levels of 25(OH)D have been related to higher severity of autism-related symptoms (44, 45). Maternal 
vitamin D deficiency has also been associated with increased offspring risk for ASD development 
(46, 47). Thus, the growing increase in the prevalence of vitamin D deficiency - observed not only in 
adults, but even in infants, children and adolescents (48, 49) - might correspond to the apparent 
increase in the prevalence of ASD during the last decades (5).  
Herein we describe the case of a 23-year-old young adult male with autism, who was referred to our 
Unit for progressive worsening of psychiatric symptoms, which gradually and substantially improved 
after vitamin D and omega-3 combination therapy initiation throughout a 24 months follow-up period. 
Written informed consent was given by the parents for permission to publish this case report. In light 
of this report, we also provided a brief review of the literature for interventional studies evaluating 
the efficacy of omega-3 or vitamin D supplementation for the treatment of ASD-related symptoms.  
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Materials and Methods 
Serum 25(OH)D levels were measured by radioimmunoassay on the Gamma Counter Wizard 1470. 
AA/EPA ratio derived from the fatty acid composition obtained from a finger stick drop of whole 
blood, which has been then analysed by gas-chromatographic analysis (50, 51). The Childhood 
Autism Rating Scale (CARS) has been administered to evaluate the degree of autism-related 
symptoms. It consists of 14 items assessing the autism-related behaviours and a 15th item rating 
general impressions of the disease. Total scores range from a minimum of 15 to a maximum of 60, 
whit higher scores being associated with a higher level of impairment. In particular, scores below 30 
correspond to the non-autistic range, scores between 30 and 36.5 correspond to mild to moderate 
autism, whereas scores ≥ 37 indicate severe autism (52, 53). The Clinical Global Impressions (CGI) 
Scale has been administered to quantify and track patient’s clinical progress and treatment response 
during the follow-up. It consists of two components: i) CGI-Severity (CGI-S), which assesses the 
average severity of symptoms basing upon observed and reported symptoms, behaviour, and function 
during the seven days just prior to the baseline visit, and ii) CGI-Improvement (CGI-I), which is 
aimed at comparing the patient’s clinical condition at any time after treatment initiation to the 1-week 
period just prior to the baseline visit. CGI-S scores range from a low of 1 to a high of 7, with score 1 
indicating a normal mental status and score 7 corresponding to the highest severity of symptoms. 
CGI-I scores range from a low of 1 to a high of 7, with score 1 indicating the best improvement after 
treatment initiation, and score 7 corresponding to the most severe clinical worsening after treatment 
initiation (54). 
Case description    
We report the case of a 23-year-old young adult male with autism, who was referred to the Unit of 
Endocrinology and Metabolic Diseases of the CTO Andrea Alesini Hospital (Department of Systems 
Medicine, University Tor Vergata, Rome, Italy) due to a 12 months history of cyclic episodes of 
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restlessness, agitation, irritability, oppositional and self-injurious behaviours. These episodes lasted 
for approximately 6-8 consecutive days each month. The patient was born at full term, after 
uncomplicated pregnancy and eutocic delivery. He was diagnosed with autism at the age of 3 years 
and 6 months by a team of neuropsychiatrists, according to the DSM-IV diagnostic criteria (55). 
Family history was negative for ASD or other psychiatric disorders. At the admission, the patient had 
been taking melatonin (3 mg/day) for insomnia and the second-generation antipsychotic risperidone 
(1 mg/day) for irritability since the age of 11 years. Moreover, he was also undergoing a cognitive 
behavioural therapy program. First physical examination revealed normal blood pressure (120/70 
mmHg), heart rate (80 bpm) and body mass index (BMI 22.9; weight 70 Kg, height 177 cm). CARS 
total score at the baseline visit was 37, indicating a condition of severe autism. CGI-S score was 5, 
indicating a condition of markedly ill mental status. Laboratory tests showed normal results, except 
for low serum levels of 25(OH)D (37.75 nmol/L; nv > 75 nmol/L), indicative of vitamin D deficiency, 
and the omega-6/omega-3 (AA/EPA) ratio, which was very high (49.54, nv < 3.0). In light of these 
findings, the patient was started on cholecalciferol plus highly purified omega-3 PUFAs 
supplementation. Cholecalciferol prescribed dose was 25.000 IU weekly in form of one single-dose 
oral solution (Dibase®; cholecalciferol 25.000 IU/2.5 mL). This dose was aimed at achieving target 
25(OH)D serum levels ≥ 75 nmol/L, which were recently reported as the minimum levels able to 
induce significant clinical improvement in ASD patients (44). Omega-3 supplementation consisted 
in the administration of ultra-refined omega-3 EPA + DHA concentrate (EnerZona® Omega 3 Rx; 
EPA 400 mg and DHA 200 mg per 1 g capsule, 2 capsules/three times daily), for a total EPA/DHA 
dose of 2.400/1.200 mg daily, corresponding to approximately 50 mg of EPA and DHA/kg body 
weight per day. This dose was aimed at achieving a target AA/EPA ratio < 3, according to previous 
findings observed in different clinical settings (50, 56-58). The patient was monitored for a total 
follow-up period of 24 months. Target 25(OH)D serum concentrations were progressively achieved 
after cholecalciferol administration, with 25(OH)D serum levels of 59.25 nmol/L, 70 nmol/L, 145.25 
nmol/L, 108.25 nmol/L, and 105.5 nmol/L, at 3, 6, 12, 18, and 24 months post-baseline visit, 
7 
 
respectively. Since the omega-3 supplementation initiation, AA/EPA gradually decreased from 49.54 
at baseline to 1.96 at 24 months post-baseline visit. Table 1 shows the changes in blood fatty acids 
composition and serum 25(OH)D observed during the follow-up. As AA/EPA ratio and serum 
25(OH)D concentrations progressively improved, remarkable improvements in symptoms were also 
gradually observed. In particular, restlessness, agitation, irritability, and self-injurious behaviours 
gradually disappeared. These improvements have been quantified through CARS total score, which 
dropped from a score suggestive of severe autism at the baseline (CARS total score: 38) to scores 
suggestive of mild to moderate autism at 12 and 24 months (35 and 33.5, respectively; see Figure 1). 
Specifically, improvements involved the following CARS items: relating to people, imitation, 
emotional response, body use, object use, visual response, nonverbal communication, and activity 
level (Figure 2). Moreover, CGI-I was administered at 3, 6, 12, 18, and 24 months, with total scores 
of 3, 2, 1, 1, and 1, respectively (Figure 1). Risperidone dose was progressively reduced during the 
follow-up (0.5 mg/day at 12 months) and definitively discontinued at 18 months, according to the 
neuropsychiatrist prescription. Melatonin dose and cognitive behavioural therapy program were not 
modified during the follow-up period. At 24 months post-baseline visit, the patient was still taking 
oral omega-3 and cholecalciferol co-supplementation at the same doses as initially prescribed. 
Importantly, no side effects were reported throughout the follow-up.   
Discussion of the case and literature review    
Clinical benefits from omega-3 supplementation have been demonstrated in various psychiatric 
disorders (23, 59, 60). Several clinical trials have been conducted to evaluate whether omega-3 can 
improve the core symptoms of ASD, with not univocal results (11). Four studies found improvements 
- although not statistically significant - in some of the ASD symptoms, such as irritability and 
hyperactivity/stereotypy (61-64). A small open-label pilot study has previously reported 
improvements in ASD symptoms after omega-3 supplementation, according to different rating scales 
(65). Conversely, Politi et al. found no significant clinical improvement after omega-3 
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supplementation in a group of nineteen young adults with severe autism (66). It is worth to note that 
the limited samples size and heterogeneity in study designs may, at least in part, account for the 
controversial results observed in different studies (11). A recent randomized, double-blind, placebo-
controlled trial conducted on children and adolescents with ASD demonstrated that omega-3 
supplementation is able to improve the erythrocyte membrane omega-6 to omega-3 ratio, without 
changing plasma antioxidant status. Social motivation also improved during the study, with no 
significant treatment effect (67). Finally, two meta-analyses assessing the effectiveness of omega-3 
fatty acids in patients with ASD showed that omega-3 supplementation leads to significant 
improvements in different ASD symptoms, including hyperactivity, lethargy, stereotypy, and 
repetitive and restricted interests and behaviours (68, 69). 
On the other hand, data on the effectiveness of vitamin D supplementation in ASD are less univocal. 
The clinical evidence that vitamin D supplementation can improve core symptoms in autism was first 
reported by Jia et al. in 2015. The authors described the case of a 32-month-old boy with ASD and 
severe vitamin D deficiency, whose autism-related symptoms significantly improved after 
cholecalciferol supplementation (150.000 IU administered intramuscularly every month, associated 
with 400 IU per day administered orally) during a 2-months follow-up period (70). Then, a 3-months 
cross-sectional study conducted on 122 ASD children found that cholecalciferol supplementation at 
the dose of 300 IU/kg/day (not to exceed 5.000 IU/day) significantly improved CARS scores when 
target serum 25(OH) ≥ 75 nmol/L was achieved (44). Similar findings have been recently replicated 
in a double-blinded randomized clinical trial conducted on 109 ASD children, where cholecalciferol 
administration at a dose of 300 IU/kg/day for 4 months led to a significant improvement in autism 
symptoms (71). Finally, an open label study conducted on thirty-seven children with ASD and 
vitamin D deficiency showed that cholecalciferol administration at large bolus doses (150.000 
IU/month administered intramuscularly) together with an oral dose of 400 IU/day gave rise to 
remarkable reductions in CARS scores, with no evidence of toxicity (45).  
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Improvement in ASD symptoms deriving from omega-3 and vitamin D co-supplementation may be 
explained by different mechanisms basing upon the ASD pathophysiology. Indeed, autistic 
individuals exhibit abnormalities in immune function at both peripheral blood and brain level, with 
increased levels of pro-inflammatory cytokines and oxidative stress, ultimately resulting in 
neuroinflammation (72-74). Moreover, the presence of multiple brain-specific autoantibodies in ASD 
children and in their mothers suggests a potential involvement of autoimmune response in the 
pathogenesis of ASD (75). Therefore, omega-3 may be effective for the treatment of ASD symptoms, 
due to their ability to reduce neuroinflammation and oxidative stress (76-78). Similarly, vitamin D 
may reduce the severity of ASD symptoms targeting the neuroinflammation through its anti-
inflammatory properties (34), increasing regulatory T cells and upregulating the master antioxidant 
agent glutathione (79-81). Vitamin D may also exert a protective effect against the autoimmune 
response, up-regulating the anti-inflammatory cytokine IL-10 (82). 1,25-dihydroxyvitamin D can 
affect the altered neurotransmitters profile typically observed in patients with ASD, increasing brain 
levels of serotonin and γ-aminobutyric acid (GABA) (83-86). Vitamin D has also been shown to 
protect brain tissue by promoting the production of neurotrophins, which counteract toxicity from 
different sources (87). Finally, omega-3 and vitamin D may exert a stronger synergistic effect on 
oxidative stress, and inflammatory and autoimmune responses, as reported in different clinical 
settings (50, 57, 58, 88).  
To date, there is only an ongoing trail assessing the effects of omega-3 and vitamin D co-
supplementation (722 mg of DHA + 2000 IU of cholecalciferol per day) on symptoms severity in 
ASD children, with results being awaited (89). To our knowledge, this is the first case reporting 
beneficial effects of omega-3 and vitamin D combination therapy on ASD symptoms, as proved by 
the marked improvements in CARS and CGI-I scores observed throughout the follow-up. Notably, 
clinical improvement corresponded to the progressive decrease of AA/EPA ratio and increase of 
DHA, along with the gradual increase of serum 25(OH)D above 100 nmol/L (Table 1). These findings 
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prompted us to make some considerations. As we previously mentioned, in patients with ASD 
AA/EPA ratio and blood levels of omega-3 PUFAs have been found to be higher and lower, 
respectively, compared to healthy controls (22, 31). Thus, AA/EPA ratio could be proposed as a 
diagnostic, prognostic and therapeutic biomarker in patients with ASD, representing a useful tool to 
titrate the dose of omega-3 fatty acids. Moreover, patients with higher AA/EPA ratio and/or lower 
omega-3 levels at baseline might show a larger therapeutic effect from omega-3 supplementation, as 
previously reported (67). It has been documented that healthy subjects taking 5 g of EPA and DHA 
per day for 10 weeks undergo an approximately 90% reduction of the AA/EPA ratio, as well as a 
significant decrease in the levels of pro-inflammatory cytokines (90). In this case study, we used total 
daily doses of EPA and DHA (50 mg of EPA and DHA/kg body weight per day) similar to those used 
previously in type 1 diabetes settings (55-70 mg of EPA and DHA/kg body weight per day), which 
successfully reduced AA/EPA ratio below 3 (50, 57, 58). It is also worth to note that different studies  
have shown that children with attention deficit hyperactivity disorder (ADHD) can tolerate higher 
daily doses of omega-3 (250-325 mg of EPA and DHA/kg body weight per day), maintaining the 
AA/EPA ratio below 3 (59, 91). Furthermore, an ongoing trial evaluating the effectiveness of omega-
3 and vitamin D co-supplementation in halting autoimmunity and disease progression in patients with 
type 1 diabetes (POSEIDON, Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type 1 
Diabetic Patients; ClinicalTrials.gov Identifier: NCT03406897) uses even greater doses of omega-3 
supplementation (150 mg of EPA and DHA/kg body weight per day) (92). 
In addition, similar to AA/EPA ratio, baseline serum 25(OH)D could also represent a potential 
predictive biomarker for vitamin D supplementation efficacy in ASD symptoms. Indeed, different 
studies and meta-analyses have found lower levels of serum 25(OH)D in children and adults with 
ASD compared to healthy controls (40-43). With regard to the therapeutic strategy, omega-3 and 
vitamin D combination therapy might be more effective than omega-3 or vitamin D supplementation 
administered alone, potentially due to their synergistic actions on oxidative stress and inflammatory 
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parameters (50, 57, 58, 88). Furthermore, most of the interventional studies on omega-3 and vitamin 
D supplementation have been conducted in children. Nonetheless, potential beneficial effects from 
this therapeutic strategy may be documented even in young adult patients with ASD, as demonstrated 
by our case. Finally, the presence of a specific subgroup of ASD patients and/or symptom clusters 
may predict the responsiveness to omega-3 and vitamin D co-supplementation. Large clinical trials 
with a proper study duration are needed to evaluate and/or confirm all the aforementioned hypotheses.  
Conclusion 
To our knowledge, this is this first case reporting significant beneficial effects of omega-3 and vitamin 
D co-supplementation on autism-related symptoms in a young adult patient. Such therapeutic 
approach could represent a safe and effective combination therapy to treat core symptoms and 
improve the quality of life in patients with ASD. This case report further underlines the importance 
of assessment of serum 25(OH)D concentrations in ASD management, in order to early detect a 
vitamin D deficiency and subsequently start an adequate vitamin D supplementation. We believe that 
also the AA/EPA ratio could represent a valid diagnostic, prognostic and therapeutic biomarker to 
start a proper omega-3 supplementation and to improve ASD-related symptoms. 
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Tables 
Table 1 - Changes in blood fatty acid composition and serum 25(OH)D observed during the whole 
follow-up period (24 months). The mean values of AA, EPA and DHA (obtained from an Italian 
population) are shown in brackets. Abbreviations: 25(OH)D, 25-hydroxyvitamin D; AA, arachidonic 
acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid. 
 Baseline 3 months 6 months 12 months 18 months 24 months 
AA 
(11.02 ± 2.10 %) 
 
12.46 9.88 12.49 5.74 10.34 9.20 
EPA 
(0.98 ± 0.40 %) 
0.25 1.96 3.48 4.30 3.87 4.70 
DHA 
(3.06 ± 1.13 %) 
2.40 3.67 4.97 4.54 4.71 4.49 
AA/EPA ratio 
 
49.54 5.05 3.59 1.34 2.67 1.96 
25(OH)D 
(deficiency: < 50 nmol/L, 
insufficiency: 52.5 - 72.5 
nmol/L) 
37.75 59.25 70 145.25 108.25 105.5 
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Figure captions  
Figure 1 - Figure shows the patient’s clinical improvement after omega-3 and vitamin D combination 
therapy initiation, as assessed by Childhood Autism Rating Scale (CARS) and Clinical Global 
Impressions (CGI) scale. CARS total score (as shown in the black box at the top right) decreased 
from 38 at the baseline (severe autism) to 35 and 33.5 (mild to moderate autism) at 12 and 24 months, 
respectively. On the other hand, Clinical Global Impressions (CGI) Scale was administered at 3, 6, 
12, 18, and 24 months, with total scores of 3, 2, 1, 1, and 1, respectively. It is important to note that 
the first score refers to CGI-Severity (CGI-S), whereas the other scores refer to CGI-Improvement 
(CGI-I).  
Figure 2 - Schematic showing the scores of the 15 different CARS items at baseline, 12 and 24 
months. Clinical improvement involved the following CARS items: relating to people, imitation, 
emotional response, body use, object use, visual response, nonverbal communication, and activity 
level. 
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